Ambrx Biopharma
Ambrx Biopharma is a clinical-stage biopharmaceutical company specializing in the development of precision-engineered antibody drug conjugates (ADCs) and other innovative protein therapeutics for the treatment of cancer and other serious diseases. Leveraging its proprietary Expanded Genetic Code technology, Ambrx Biopharma creates targeted therapies designed to improve efficacy and safety profiles for patients. The company’s robust pipeline includes multiple investigational candidates in various stages of clinical development, reflecting its commitment to advancing next-generation biologics. Ambrx Biopharma collaborates with leading global pharmaceutical partners to accelerate the discovery and commercialization of novel therapeutics, aiming to address unmet medical needs and improve patient outcomes worldwide.
